How to treat NTM pulmonary disease: ATS/ERS/ESCMID/IDSA clinical practice guideline 2020

This module will review the recommendations from the new guidelines for the treatment of NTM pulmonary disease.

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. Pulmonary disease due to NTM is increasing in many areas of the world. The most common NTM to cause pulmonary disease in most areas are the slow growers, M. avium complex, M. kansasii, M. xenopi and rapid growers, M. abscessus and its three subspecies. Diagnosis of NTM pulmonary disease requires the synthesis of clinical, radiological and microbiologic data. Treatment of NTM pulmonary disease varies depending on the specific NTM causing disease and requires administration of multidrug regimens administered for 12 or more months beyond culture conversion.

Access the full module

CME Online

More content like this

Access the CME Online archive to watch past modules.

Visit the archive